Back to top
more

Galectin Therapeutics (GALT)

(Real Time Quote from BATS)

$2.89 USD

2.89
15,247

-0.16 (-5.25%)

Updated May 28, 2024 10:23 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for GALT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Galectin Therapeutics Inc. [GALT]

Reports for Purchase

Showing records 101 - 107 ( 107 total )

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 101

11/25/2013

Company Report

Pages: 8

Phase 1 for GR-MD-02 well underway and preclinical data published in medical journa

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 102

07/23/2013

Company Report

Pages: 2

We are transferring coverage as a result of reorganization of our coverage universe

Provider: STONEGATE CAPITAL MARKETS

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 103

05/20/2013

Company Report

Pages: 20

Initiation of Coverage - Blocking and tackling its way to opportunities in liver fibrosis and cancer

Provider: STONEGATE CAPITAL MARKETS

Analyst: RODRIGUEZ M

Price: 50.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 104

02/13/2013

Daily Note

Pages: 4

We are terminating research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.

Provider: DAWSON JAMES SECURITIES, INC.

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 105

07/06/2012

Company Report

Pages: 6

September Symposium to Highlight Galectin-based Platform

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 106

11/30/2011

Company Report

Pages: 5

GALT: Targeting Hot Liver Disorder Area; Maintain Buy rating

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 10.00

Research Provided by a Third Party

Company: Galectin Therapeutics Inc.

Industry: Medical - Drugs

Record: 107

09/06/2011

Company Report

Pages: 22

Initiating Coverage with a Buy Rating and Price Target of $4

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: BERNARDINO V

Price: 75.00

Research Provided by a Third Party